TG Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
TG Therapeutics, Inc. (TGTX) filed this Current Report on Form 8-K on December 30, 2021, regarding an event reported on the same date. The Company is a Delaware corporation listed on the Nasdaq Capital Market.
Key Financial Metrics and Transaction Details
The filing details the entry into an Amended and Restated Loan and Security Agreement with Hercules Capital, Inc. Key financial terms include:
- Total Facility Size: Increased from $60.0 million to $200.0 million.
- Initial Advance: $70.0 million drawn at closing.
- Refinancing: Approximately $7.8 million of the initial advance was used to refinance the outstanding balance of the prior loan.
- Future Tranches:
- Tranche 2: Increased to $20.0 million (subject to milestones).
- Tranche 3: Increased to $45.0 million (subject to milestones).
- Tranche 4: Increased to $65.0 million (subject to approval).
- Interest Rate: The greater of (a) Prime Rate + 2.15% or (b) 5.40%.
- Warrant Coverage: 2.95% of total funded amount; 115,042 shares issued with an exercise price of $17.95.
Material Changes Versus Prior Period
Compared to the original Loan Agreement dated February 28, 2019, the Amendment introduces significant changes:
- Maturity Date: Extended from March 1, 2022, to January 1, 2026.
- Interest-Only Period: Reset and extended from April 1, 2021, to February 1, 2025 (potentially extendable to August 1, 2025 based on milestones).
- Covenants: New financial covenants require maintaining specific levels of unrestricted cash starting October 15, 2022. Additional covenants related to market capitalization and cash levels apply from July 1, 2023, if advances exceed $70 million.
Outlook, Risks, and Management Commentary
Proceeds from the facility are designated for ongoing research and development programs, commercialization activities, and general corporate purposes. The loan structure is heavily tied to performance milestones, specifically U.S. Food and Drug Administration (FDA) approvals, which impact the interest-only period extension, access to future tranches, and minimum cash requirements. The filing notes that the description is qualified by reference to the full agreement to be filed as an exhibit to the next Form 10-K.
Investor Verification Checklist
- Verify the specific FDA approval milestones required to unlock Tranches 2 and 3 and extend the interest-only period.
- Confirm the current unrestricted cash balance to assess compliance with covenants effective October 15, 2022.
- Review the full text of the Amended and Restated Loan and Security Agreement (Exhibit 10) in the subsequent Form 10-K for detailed default provisions.
- Monitor the Company's market capitalization relative to the covenant thresholds effective July 1, 2023.